First patient treated in Hansa Medical’s Highdes-study

Hansa Medical AB (publ) today announced that the first patient has been treated and subsequently transplanted in the pivotal multicenter study Highdes using IdeS to desensitize highly sensitized patients prior to kidney transplantation.The Phase II study will include approximately 20 highly sensitized patients awaiting kidney transplantation. Patients included in this new study have either failed on previous attempts of desensitization or the currently available methods are considered insufficiently effective. The study is entitled “A Phase II Study to Evaluate the Efficacy of IdeS (IgG